Your browser is no longer supported. Please, upgrade your browser.
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.09 Insider Own0.80% Shs Outstand176.69M Perf Week6.60%
Market Cap2.39B Forward P/E- EPS next Y-0.72 Insider Trans-12.06% Shs Float175.06M Perf Month24.11%
Income-182.80M PEG- EPS next Q-0.27 Inst Own68.60% Short Float14.27% Perf Quarter33.89%
Sales17.80M P/S134.32 EPS this Y-16.00% Inst Trans-0.56% Short Ratio4.58 Perf Half Y227.09%
Book/sh-0.11 P/B- EPS next Y30.10% ROA-84.80% Target Price14.56 Perf Year234.72%
Cash/sh1.62 P/C7.96 EPS next 5Y19.90% ROE-773.60% 52W Range3.30 - 14.24 Perf YTD73.42%
Dividend- P/FCF- EPS past 5Y-13.10% ROI-69.30% 52W High-9.27% Beta2.67
Dividend %- Quick Ratio3.00 Sales past 5Y-18.10% Gross Margin90.60% 52W Low291.52% ATR0.76
Employees246 Current Ratio3.10 Sales Q/Q-89.90% Oper. Margin- RSI (14)62.30 Volatility8.97% 6.89%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume3.29 Prev Close10.68
ShortableYes LT Debt/Eq- EarningsMay 06 BMO Payout- Avg Volume5.45M Price12.92
Recom2.00 SMA2015.01% SMA5013.70% SMA20080.57% Volume17,957,403 Change20.97%
Mar-01-21Initiated Cowen Outperform $16
Sep-29-20Resumed JP Morgan Overweight $7
Jun-17-20Initiated BTIG Research Neutral
May-05-20Upgrade Barclays Equal Weight → Overweight $7
Nov-15-19Upgrade BofA/Merrill Neutral → Buy $5 → $4
May-24-19Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18Resumed Piper Jaffray Overweight $15
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
May-06-21 09:31PM  
May-05-21 07:00AM  
Apr-30-21 09:22AM  
Apr-29-21 05:03PM  
Apr-22-21 07:00AM  
Apr-20-21 09:30AM  
Apr-14-21 03:42PM  
Apr-08-21 01:19AM  
Apr-07-21 07:00AM  
Mar-24-21 12:16PM  
Mar-22-21 01:27PM  
Mar-19-21 07:00AM  
Mar-15-21 07:00AM  
Mar-11-21 08:30AM  
Mar-02-21 07:00AM  
Mar-01-21 02:00PM  
Feb-26-21 06:31AM  
Feb-25-21 04:15PM  
Feb-18-21 07:00AM  
Feb-11-21 07:00AM  
Feb-09-21 07:15AM  
Feb-08-21 10:11AM  
Feb-07-21 01:27AM  
Feb-03-21 07:00AM  
Feb-02-21 11:37AM  
Feb-01-21 04:54PM  
Jan-28-21 08:34AM  
Jan-25-21 09:28AM  
Jan-22-21 10:58AM  
Jan-07-21 07:00AM  
Jan-06-21 07:00AM  
Dec-23-20 10:15AM  
Dec-22-20 11:42AM  
Dec-21-20 10:01AM  
Dec-18-20 08:28PM  
Dec-16-20 07:00AM  
Dec-11-20 07:00AM  
Dec-09-20 01:10PM  
Dec-08-20 11:50PM  
Dec-07-20 08:45AM  
Dec-06-20 10:00AM  
Dec-04-20 12:59PM  
Dec-03-20 08:45PM  
Dec-01-20 04:15PM  
Nov-30-20 07:00AM  
Nov-20-20 07:00AM  
Nov-13-20 07:59AM  
Nov-12-20 07:00AM  
Nov-07-20 08:01AM  
Nov-05-20 11:01PM  
Nov-02-20 04:15PM  
Oct-30-20 08:15AM  
Oct-29-20 12:35PM  
Oct-28-20 07:31AM  
Oct-22-20 04:15PM  
Oct-07-20 08:34AM  
Oct-05-20 04:15PM  
Sep-30-20 07:00AM  
Sep-28-20 03:09PM  
Sep-22-20 07:25AM  
Sep-08-20 07:00AM  
Sep-03-20 04:15PM  
Aug-31-20 09:29AM  
Aug-17-20 11:41AM  
Aug-13-20 01:48PM  
Aug-11-20 08:54AM  
Aug-06-20 09:55AM  
Aug-04-20 07:00AM  
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jones Michael LExec. Director, Finance - PAOMar 18Option Exercise3.514,50015,7955,348Mar 22 04:19 PM
Sheridan William PSenior VP - CMOFeb 22Option Exercise4.1541,250171,18852,725Feb 24 04:34 PM
Sheridan William PSenior VP - CMOFeb 22Sale11.5741,250477,26211,475Feb 24 04:34 PM
Babu Yarlagadda SSenior VP - Drug DiscoveryFeb 19Option Exercise4.1550,000207,500205,587Feb 23 04:25 PM
Stonehouse Jon PPresident & CEODec 15Option Exercise4.15134,278557,254918,364Dec 17 04:20 PM
Stonehouse Jon PPresident & CEODec 15Sale8.32134,2781,117,193784,086Dec 17 04:20 PM
Barnes Alane PSenior VP, Chief Legal OfficerDec 11Option Exercise4.1513,74157,025121,802Dec 15 05:35 PM
Barnes Alane PSenior VP, Chief Legal OfficerDec 11Sale7.9613,741109,378108,061Dec 15 05:35 PM
Barnes Alane PSenior VP, Chief Legal OfficerDec 04Option Exercise4.1513,74157,025121,802Dec 08 04:12 PM
Barnes Alane PSenior VP, Chief Legal OfficerDec 04Sale6.2313,74185,606108,061Dec 08 04:12 PM
Doyle AnthonyChief Financial OfficerAug 11Buy4.0854,000220,32054,000Aug 12 04:31 PM